Valuation: Alnylam Pharmaceuticals, Inc.

Market Cap 31.1B 27.85B 25.7B 23.25B 43.48B 2,961B 44.19B 307B 122B 1,550B 117B 114B 4,909B P/E 2026 *
35x
P/E 2027 * 24.1x
Enterprise Value 28.11B 25.18B 23.23B 21.02B 39.3B 2,677B 39.94B 277B 111B 1,401B 105B 103B 4,437B EV / Sales 2026 *
5.13x
EV / Sales 2027 * 3.81x
Free-Float
99.82%
Yield 2026 *
-
Yield 2027 * -
1 day-24.53%
1 week-22.00%
Current month-28.15%
1 month-30.23%
3 months-38.15%
6 months-41.14%
Current year-55.42%
1 week 172.31
Extreme 172.31
232.88
1 month 172.31
Extreme 172.31
254.44
Current year 172.31
Extreme 172.31
427.05
1 year 172.31
Extreme 172.31
479.79
3 years 141.98
Extreme 141.975
495.55
5 years 117.58
Extreme 117.58
495.55
10 years 31.38
Extreme 31.38
495.55
Manager TitleAgeSince
Chief Executive Officer 63 01/01/2022
Director of Finance/CFO 58 13/08/2019
Chief Tech/Sci/R&D Officer - 01/04/2023
Director TitleAgeSince
Director/Board Member 80 23/04/2012
Chairman 65 05/01/2023
Director/Board Member 72 18/12/2015
Date Insider Type Main position Quantity % Market Cap. Importance
10/2/26 A Sell

General Counsel

-1,758 0.0013%
9/19/26 A Free

Chief Executive Officer

107 0.0001%
6/1/26 A Exercice

Director

11,490 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
-24.61%-22.00%-63.19%+17.08% 31.1B
+6.25%+4.65%+68.09%+141.73% 1,148B
+1.60%+2.74%+47.35%+87.01% 652B
+1.40%+1.37%+28.40%+103.74% 505B
+0.73%+2.45%+54.26%+66.47% 384B
+4.49%-0.23%+69.68%+43.07% 348B
+2.38%+2.65%+34.31%+56.33% 294B
+2.26%+0.55%+3.92%+27.74% 264B
+2.00%+2.83%+57.64%+74.76% 244B
+2.77%+3.02%+36.66%+108.23% 197B
Average -0.05%+1.57%+33.71%+72.62% 406.83B
Weighted average by Cap. +3.03%+1.52%+48.91%+92.54%

Financials

2026 *2027 *
Net sales 5.48B 4.91B 4.53B 4.1B 7.66B 522B 7.79B 54.02B 21.55B 273B 20.56B 20.13B 865B 6.92B 6.2B 5.72B 5.18B 9.68B 659B 9.83B 68.23B 27.22B 345B 25.97B 25.42B 1,092B
Net income 906M 812M 749M 678M 1.27B 86.32B 1.29B 8.94B 3.57B 45.18B 3.4B 3.33B 143B 1.3B 1.17B 1.08B 973M 1.82B 124B 1.85B 12.83B 5.12B 64.85B 4.88B 4.78B 205B
Net Debt -2.99B -2.68B -2.47B -2.24B -4.18B -285B -4.25B -29.48B -11.76B -149B -11.22B -10.98B -472B -4.75B -4.25B -3.92B -3.55B -6.64B -452B -6.74B -46.78B -18.66B -237B -17.81B -17.43B -749B
Projected Income Statement - Annual - Alnylam Pharmaceuticals, Inc.
Logo Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development, manufacture, and commercialization of therapeutics based on RNA interference technology, The company offers treatments for rare and chronic diseases, including cardiovascular diseases, acute hepatic porphyria, hypercholesterolemia, and transthyretin amyloidosis with neurological involvement. At the end of 2025, Alnylam Pharmaceuticals, Inc. had a portfolio of 5 products on the market and several candidates in clinical development. Net sales are distributed geographically as follows: the United States (69.2%), Europe (21.8%) and other (9%).
Employees
2,500
Date Price Change Volume
29/10/26 $177.20 -23.75% 8,408,136
28/10/26 $232.40 +2.47% 1,944,031
27/10/26 $226.79 -0.38% 1,603,484
26/10/26 $227.66 +1.62% 1,436,998
23/10/26 $224.03 -1.43% 1,055,960
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Alnylam Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
232.40USD
Average target price
367.78USD
Spread / Average Target
+58.25%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alnylam Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ALNY Stock